文献速递前列腺癌

雄激素剥夺治疗中睾酮突破率综述

Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
PubMed 文献 · J Urol · 2020-02-25

本综述系统检索45项研究、52个队列共6047例接受雄激素剥夺治疗的去势敏感性前列腺癌患者,汇总睾酮突破率数据。结果显示0.7 nmol/l阈值下加权平均突破率显著高于1.7 nmol/l阈值(41.3% vs 6.9%,p<0.0001),突破率与更差临床结局的总体关联不显著,但在大样本和高事件率研究中观察到显著关联。作者认为应避免睾酮突破并标准化睾酮检测。

要点

  • 0.7 nmol/l阈值下睾酮突破率显著高于1.7 nmol/l(41.3% vs 6.9%)。
  • 总体突破率与临床结局关联不显著,大样本高事件率研究中有显著关联。
  • 给药与监测频率、检测方法及ADT类型未显著影响突破率。

核心结论

  • 睾酮突破可能导致更差的临床结局,应予以避免。
  • 临床与研究中的睾酮水平评估需要标准化,以改善治疗决策和结果可比性。

研究设计与样本

  • 系统综述,纳入45项研究、52个队列、共6047例接受雄激素剥夺治疗的去势敏感性前列腺癌患者。
  • 突破率数据覆盖1.7 nmol/l阈值(51个队列,6015例)和0.7 nmol/l阈值(15个队列,2495例)。

主要发现

  • 0.7 nmol/l阈值下加权平均突破率为41.3%,显著高于1.7 nmol/l阈值的6.9%(p<0.0001)。
  • 突破率与更差临床结局的总体关联不显著。
  • 在样本量大于100且事件率大于50%的研究中,最低阈值下突破率与临床结局存在显著关联。
  • 给药与监测频率、睾酮检测类型及ADT类型未显著影响突破率,但非验证检测方法变异性大。

关键数值与推荐

  • 睾酮突破定义为雄激素剥夺治疗首月后睾酮升高超过目标阈值。
  • 阈值包括1.7 nmol/l和0.7 nmol/l,后者与更差结局相关。

临床怎么用

  • 临床中应监测睾酮水平,避免突破至0.7 nmol/l以上。
  • 优先使用验证过的睾酮检测方法,并标准化监测频率与评估流程。

局限性

  • 总体分析未发现突破率与临床结局的显著关联,仅在大样本高事件率研究中观察到。
  • 非验证睾酮检测方法导致较大变异性,可能影响结果可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Androgen deprivation therapy is an established therapy for castration sensitive prostate cancer and recent studies have observed that patients whose testosterone levels are suppressed below 0.7 nmol/l have improved outcomes. Testosterone breakthrough, or a rise in testosterone above a target threshold after the first month of androgen deprivation therapy, is generally associated with treatment deficiency. The purpose of this review is to summarize breakthrough rate data and explore the relationship to clinical outcomes in patients with castration sensitive prostate cancer receiving androgen deprivation therapy. MATERIALS AND METHODS: Our systematic search identified 45 studies with a total of 52 cohorts representing 6,047 total patients reporting testosterone breakthrough rates or derivative measures above the thresholds of 1.7 nmol/l (51 cohorts, 6,015 patients) or 0.7 nmol/l (15 cohorts, 2,495 patients). RESULTS: Significantly higher weighted mean breakthrough rates were seen for the 0.7 nmol/l threshold compared to 1.7 nmol/l (41.3% vs 6.9%, p <0.0001). A significant association between breakthrough rates and worse clinical outcomes overall was not found, although when larger trials (sample size greater than 100) and higher event rates (greater than 50%) were considered for the lowest threshold, significant associations between breakthrough rates and clinical outcomes were observed. Clinical factors such as administration and monitoring frequency, type of testosterone assay and type of androgen deprivation therapy did not significantly affect breakthrough rates, although nonvalidated assays were associated with a large degree of variability. CONCLUSIONS: Results from our analysis indicate that testosterone breakthroughs likely result in worse clinical outcomes and should be avoided. Moreover, there is a need to standardize assessment of testosterone levels both clinically and in the research context to better inform treatment decisions and improve the reliability and comparability of results across studies.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Saad F, Fleshner N, Pickles T, et al. Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. J Urol. 2020. PMID: 32096678. doi:10.1097/JU.0000000000000809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。